Reuters logo
BRIEF-Zymeworks presents additional safety and anti-tumor activity data from ongoing phase 1 study of ZW25
September 11, 2017 / 2:15 PM / 3 months ago

BRIEF-Zymeworks presents additional safety and anti-tumor activity data from ongoing phase 1 study of ZW25

Sept 11 (Reuters) - Zymeworks Inc

* Zymeworks presents additional safety and anti-tumor activity data from the ongoing phase 1 study of zw25 at the european society for medical oncology 2017 congress (“ESMO”)

* Zymeworks inc - ‍ZW25 continues to be well-tolerated at all doses and schedules​

* Zymeworks inc - ‍dose escalation portion of phase 1 trial is complete and new expansion cohorts have begun enrolling​

* Zymeworks inc - ‍ZW25 was well-tolerated at all dose levels evaluated​

* Zymeworks inc - ‍safety and anti-tumor activity profile of ZW25 across multiple dose levels suggests potential for a wide therapeutic window​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below